CoChat

Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: To evaluate the clinical safety of daily tenofovir disoproxil fumarate (TDF) among HIV-negative men who have sex with men. DESIGN: Randomized, double-blind, placebo-controlled trial. Participants were randomized 1:1:1:1 to immediate or delayed study drug (TDF, 300 mg orally per day, or placebo). METHODS: Four hundred healthy HIV-uninfected men who have sex with men reporting anal sex with another man within the previous 12 months enrolled in Atlanta, Boston, and San Francisco. HIV serostatus, clinical and laboratory adverse events (AEs), adherence (pill count, Medication Event Monitoring System, and self-report), and sexual and other sociobehavioral data were assessed at 3-month intervals for 24 months. Primary outcomes were clinical safety, assessed by incidence of AEs and laboratory abnormalities. RESULTS: Study drug was initiated by 373 (93%) participants (186 TDF and 187 placebo), of whom 325 (87%) completed the final study visit. Of 2428 AEs reported among 334 (90%) participants, 2366 (97%) were mild or moderate in severity. Frequencies of commonly reported AEs did not differ significantly between TDF and placebo arms. In multivariable analyses, back pain was more likely among TDF recipients (P = 0.04); these reports were not associated with documented fractures or other objective findings. There were no grade ≥3 creatinine elevations; grades 1 and 2 creatinine increases were not associated with TDF receipt. Estimated percentage of study drug doses taken was 92% by pill count and 77% by Medication Event Monitoring System. Seven seroconversions occurred: 4 on placebo and 3 among delayed arm participants not yet on study drug. CONCLUSIONS: Daily oral TDF was well tolerated, with reasonable adherence. No significant renal concerns were identified.

Overview

Integrity signals

Registry

Crossref · 10.1097/qai.0b013e31828ece33

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. 2011, Thirty years of HIV1981-2011., MMWR Morb Mortal Wkly Rep, 60, 689
  2. 2011, HIV surveillanceUnited States, 1981-2008., MMWR Morb Mortal Wkly Rep, 60, 65

Cited by

See all 172

Metadata

Authors
Grohskopf, L. A., Chillag, K. L., Gvetadze, R., Liu, A. Y., Thompson, M., Mayer, K. H., Collins, B. M., Pathak, S. R., O'Hara, B., Ackers, M. L., Rose, C. E., Grant, R. M., Paxton, L. A., & Buchbinder, S. P.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • AIDS Research Consortium of Atlanta (US)
  • Beth Israel Deaconess Medical Center (US)
  • Northrop Grumman (United States) (US)
  • Gladstone Institutes (US)
Corresponding author
  • Grohskopf, Lisa A.
  • Chillag, Kata L.
  • Ackers, Marta L.
  • Paxton, Lynn A.
Venue
JAIDS Journal of Acquired Immune Deficiency Syndromes
Published
2013-09-01
Volume
64
Issue
1
Pages
79-86
ISSN
1525-4135 (ISSN-L)
OpenAlex
W2331361632
Cited by
172
References
32
Citations by year
2026: 1 · 2025: 6 · 2024: 7 · 2023: 13 · 2022: 15 · 2021: 19 · 2020: 9 · 2019: 12 · 2018: 20 · 2017: 17 · 2016: 24 · 2015: 15 · 2014: 10 · 2013: 2
FWCI
12.35
Type
journal article
Language
en
Open access
closed
Locations
  • JAIDS Journal of Acquired Immune Deficiency Syndromes (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Public Health Service (200-2003-03007, 200-2003-03003, 200-2004-09853)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords
tenofovir disoproxil fumarate, HIV prevention, pre-exposure prophylaxis, clinical safety, adverse events, medication adherence, back pain, renal safety, creatinine elevation, seroconversion, anal sex
MeSH terms
Tenofovir, Adenine, Adolescent, Boston, Double-Blind Method, Follow-Up Studies, Georgia, Humans, Male, Middle Aged, San Francisco, HIV Infections, Treatment Outcome, Drug Monitoring, Hypophosphatemia, HIV Seronegativity, Homosexuality, Male, CD4 Lymphocyte Count, Anti-HIV Agents, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.